Abstract
This open-label, dose-escalation study assessed the maximum tolerated dose (MTD) of the new antifungal micafungin in patients undergoing haematopoietic stem cell transplantation (HSCT). Participants received 3, 4, 6 or 8 mg/kg/day micafungin intravenously from 7 days to a maximum of 28 days or until neutropaenia resolved. The MTD was defined as the highest dose not causing the same Grade 3 or 4 adverse event in three or more patients. All 36 participants received ⩾8 days treatment for a median of 18 days (range: 8–28); 1 patient withdrew consent and a further 11 discontinued to receive another systemic antifungal agent for a suspected infection. No case of confirmed invasive fungal infection occurred. Adverse events were those expected for patients undergoing HSCT and showed no evidence of dose-related toxicity. Criteria for MTD were not met; no patient had a Grade 3 or 4 adverse event considered causally related to micafungin. Thus, the MTD of micafungin can be inferred to be 8 mg/kg/day or higher.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551–573.
Prentice AG, Barnes RA, Rogers TRF, Cohen J, Denning DW, Evans EGV et al. Therapy of deep fungal infection in hematological malignancy. J Antimicrob Chemother 1997; 40: 779–788.
Donnelly JP, De Pauw BE . Voriconazole – a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004; 10 (Suppl 1): 107–117.
Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S . Antifungal prophylaxis for severely neutropenic chemotherapy patients: a meta-analysis of randomized controlled trials. Cancer 2002; 94: 3230–3246.
Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 15: 4615–4626.
Mora-Duarte J, Betts R, Rotstein C, Lopes Colombo A, Thompson-Moya L, Smietana J . Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 25: 2020–2029.
Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571.
Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 30: 1391–1402.
Hiemenz J, Gagnoni P, Simpson D, Devine S, Chao N, Keirns J et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for the prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331–1336.
Green S, Weiss GR . Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239–253.
Guiot HFL, Fibbe WL, van't Wout JW . Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empiric therapy and prophylaxis. Clin Infect Dis 1994; 18: 525–532.
Groll AH, Walsh TJ . FK463, Fujisawa Pharmaceutical Co Ltd. Curr Opin Anti-infect Invest Drugs 2000; 2: 405–412.
Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57–62.
Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E, Tawara S et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44: 614–618.
Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S . Efficacy of FK463, a (1,3)-ß-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000; 44: 1728–1730.
Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000; 44: 619–621.
de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842–849.
Herbert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954–960.
Herbert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 1018–1024.
van Burik JA, Ratanatharathorn V, Stepan DE, Millr CB, Lipton JH, Vesole DH et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–1416.
Acknowledgements
This study was sponsored by Astellas Pharma GmbH (protocol number FG463-21-03). We thank Dorothea Wessiepe for management of the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sirohi, B., Powles, R., Chopra, R. et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 38, 47–51 (2006). https://doi.org/10.1038/sj.bmt.1705398
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705398
Keywords
This article is cited by
-
Updates in the Treatment of Breakthrough Mold Infections
Current Fungal Infection Reports (2020)
-
Extrapolating Antifungal Animal Data to Humans—Is It Reliable?
Current Fungal Infection Reports (2020)
-
Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations
European Journal of Clinical Pharmacology (2020)
-
Efficacy and safety of micafungin in unrelated cord blood transplant recipients
Annals of Hematology (2019)
-
Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients
Critical Care (2018)